Status:
COMPLETED
Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Irritable Bowel Syndrome Without Diarrhea
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.
Eligibility Criteria
Inclusion
- Aged 18-75 years who satisfied RomeIII criteria for the diagnosis of IBS
- Signed informed consent
Exclusion
- IBS-D
- evidence of cathartic colon or history laxative abuse
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT01505777
Start Date
May 1 2011
End Date
June 1 2012
Last Update
April 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
16 institutions including Gangnam Severance hospital
Seoul, South Korea